Home › All Companies › COGT › Quarterly Report

Cogent Biosciences, Inc. (COGT) — Quarterly Report

AI-Powered SEC Filing Analysis

← All COGT filings
Latest Quarterly Report Filed: 2026-05-05

Key Insights

  • The filing date of 2026-05-05 for Q1 2025 (ended 2025-03-31) represents a significant reporting delay, suggesting potential operational or administrative challenges that warrant investor scrutiny.
  • Multiple convertible debt and preferred stock instruments are present (Convertible Senior Notes Due 2031, Series A and B Non-Voting Convertible Preferred Stock), indicating capital structure complexity and potential dilution risk to common shareholders.
  • The presence of extensive stock-based compensation arrangements (employee stock purchase plans, stock options, restricted stock units with performance conditions) suggests substantial equity dilution ongoing, which may pressure EPS and shareholder value.
Sentiment: Neutral Significance: 4/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-05-05. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Cogent Biosciences, Inc.

Current Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.